BCAX — Bicara Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Bicara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 4.16 | 230 | 490 | 415 |
| Prepaid Expenses | ||||
| Total Current Assets | 4.98 | 231 | 503 | 422 |
| Net Property, Plant And Equipment | 0.636 | 0.815 | 0.845 | 2.03 |
| Other Long Term Assets | ||||
| Total Assets | 6.7 | 234 | 510 | 431 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 23.9 | 15.1 | 18 | 28.9 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 24 | 15.5 | 18.1 | 29.5 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -17.3 | 219 | 492 | 401 |
| Total Liabilities & Shareholders' Equity | 6.7 | 234 | 510 | 431 |
| Total Common Shares Outstanding |